Yonsei Med J.  2017 Mar;58(2):347-354. 10.3349/ymj.2017.58.2.347.

Parameters of Glucose and Lipid Metabolism Affect the Occurrence of Colorectal Adenomas Detected by Surveillance Colonoscopies

• Kim NH
• Suh JY
• Park JH
• Park DI
• Cho YK
• Sohn CI
• Choi K
• Jung YS

• KMID: 2427123
• DOI: http://doi.org/10.3349/ymj.2017.58.2.347

Abstract

PURPOSE
Limited data are available regarding the associations between parameters of glucose and lipid metabolism and the occurrence of metachronous adenomas. We investigated whether these parameters affect the occurrence of adenomas detected on surveillance colonoscopy.
MATERIALS AND METHODS
This longitudinal study was performed on 5289 subjects who underwent follow-up colonoscopy between 2012 and 2013 among 62171 asymptomatic subjects who underwent an initial colonoscopy for a health check-up between 2010 and 2011. The risk of adenoma occurrence was assessed using Cox proportional hazards modeling.
RESULTS
The mean interval between the initial and follow-up colonoscopy was 2.2±0.6 years. The occurrence of adenomas detected by the follow-up colonoscopy increased linearly with the increasing quartiles of fasting glucose, hemoglobin A1c (HbA1c), insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and triglycerides measured at the initial colonoscopy. These associations persisted after adjusting for confounding factors. The adjusted hazard ratios for adenoma occurrence comparing the fourth with the first quartiles of fasting glucose, HbA1c, insulin, HOMA-IR, and triglycerides were 1.50 [95% confidence interval (CI), 1.26-1.77; p(trend)<0.001], 1.22 (95% CI, 1.04-1.43; p(trend)=0.024), 1.22 (95% CI, 1.02-1.46; p(trend)=0.046), 1.36 (95% CI, 1.14-1.63; p(trend)=0.004), and 1.19 (95% CI, 0.99-1.42; p(trend)=0.041), respectively. In addition, increasing quartiles of low-density lipoprotein-cholesterol and apolipoprotein B were associated with an increasing occurrence of adenomas.
CONCLUSION
The levels of parameters of glucose and lipid metabolism were significantly associated with the occurrence of adenomas detected on surveillance colonoscopy. Improving the parameters of glucose and lipid metabolism through lifestyle changes or medications may be helpful in preventing metachronous adenomas.

Keyword

Colorectal adenoma; surveillance; glucose metabolism; dyslipidemia

MeSH Terms

Adenoma/blood/*diagnosis
Apolipoproteins B/metabolism
Cholesterol, LDL/metabolism
*Colonoscopy
Colorectal Neoplasms/blood/*diagnosis
Fasting/metabolism
Female
Glucose/*metabolism
Glycated Hemoglobin A/analysis
Humans
Insulin/metabolism
*Lipid Metabolism
Longitudinal Studies
Male
Proportional Hazards Models
Risk
Risk Factors
Triglycerides/metabolism
Apolipoproteins B
Cholesterol, LDL
Glycated Hemoglobin A
Insulin
Triglycerides
Glucose

Figure

• 

  Fig. 1 Flow diagram illustrating the selection of study subjects.

Reference

1. Lee HS, Jeon SW. Is retroflexion helpful in detecting adenomas in the right colon?: a single center interim analysis. Intest Res. 2015; 13:326–331.

2. Lin OS, Kozarek RA, Cha JM. Impact of sigmoidoscopy and colonoscopy on colorectal cancer incidence and mortality: an evidence-based review of published prospective and retrospective studies. Intest Res. 2014; 12:268–274.

3. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012; 143:844–857.

4. Luo S, Li JY, Zhao LN, Yu T, Zhong W, Xia ZS, et al. Diabetes mellitus increases the risk of colorectal neoplasia: an updated meta-analysis. Clin Res Hepatol Gastroenterol. 2016; 40:110–123.

5. Kim BC, Shin A, Hong CW, Sohn DK, Han KS, Ryu KH, et al. Association of colorectal adenoma with components of metabolic syndrome. Cancer Causes Control. 2012; 23:727–735.

6. Liu CS, Hsu HS, Li CI, Jan CI, Li TC, Lin WY, et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol. 2010; 10:51.

7. Park H, Ko SH, Lee JM, Park JH, Choi YH. Troglitazone enhances the apoptotic response of DLD-1 colon cancer cells to photodynamic therapy. Yonsei Med J. 2016; 57:1494–1499.

8. Keku TO, Lund PK, Galanko J, Simmons JG, Woosley JT, Sandler RS. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2005; 14:2076–2081.

9. Rampal S, Yang MH, Sung J, Son HJ, Choi YH, Lee JH, et al. Association between markers of glucose metabolism and risk of colorectal adenoma. Gastroenterology. 2014; 147:78–87.

10. Vidal AC, Lund PK, Hoyo C, Galanko J, Burcal L, Holston R, et al. Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. BMC Cancer. 2012; 12:389.

11. Ortiz AP, Thompson CL, Chak A, Berger NA, Li L. Insulin resistance, central obesity, and risk of colorectal adenomas. Cancer. 2012; 118:1774–1781.

12. Misciagna G, De Michele G, Guerra V, Cisternino AM, Di Leo A, Freudenheim JL. INTEROSP Group. Serum fructosamine and colorectal adenomas. Eur J Epidemiol. 2004; 19:425–432.

13. Yamada K, Araki S, Tamura M, Sakai I, Takahashi Y, Kashihara H, et al. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol. 1998; 27:794–798.

14. Yang MH, Rampal S, Sung J, Choi YH, Son HJ, Lee JH, et al. The association of serum lipids with colorectal adenomas. Am J Gastroenterol. 2013; 108:833–841.

15. Bayerdörffer E, Mannes GA, Richter WO, Ochsenkühn T, Seeholzer G, Köpcke W, et al. Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann Intern Med. 1993; 118:481–487.

16. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut. 2011; 60:1094–1102.

17. Jung YS, Ryu S, Chang Y, Yun KE, Park JH, Kim HJ, et al. Associations between parameters of glucose and lipid metabolism and risk of colorectal neoplasm. Dig Dis Sci. 2015; 60:2996–3004.

18. Taniguchi L, Higurashi T, Uchiyama T, Kondo Y, Uchida E, Uchiyama S, et al. Metabolic factors accelerate colorectal adenoma recurrence. BMC Gastroenterol. 2014; 14:187.

19. Jacobs ET, Martínez ME, Alberts DS, Jiang R, Lance P, Lowe KA, et al. Association between body size and colorectal adenoma recurrence. Clin Gastroenterol Hepatol. 2007; 5:982–990.

20. Laiyemo AO, Doubeni C, Badurdeen DS, Murphy G, Marcus PM, Schoen RE, et al. Obesity, weight change, and risk of adenoma recurrence: a prospective trial. Endoscopy. 2012; 44:813–818.

21. So H, Han S, Park HW, Kim EH, Lee JY, Lee HS, et al. Metabolic factors affect the occurrence of colorectal neoplasm on surveillance colonoscopies. J Gastroenterol Hepatol. 2016; 31:1273–1279.

22. Chiu HM, Lee YC, Tu CH, Chang LC, Hsu WF, Chou CK, et al. Effects of metabolic syndrome and findings from baseline colonoscopies on occurrence of colorectal neoplasms. Clin Gastroenterol Hepatol. 2015; 13:1134–1142.

23. Lin CC, Huang KW, Luo JC, Wang YW, Hou MC, Lin HC, et al. Hypertension is an important predictor of recurrent colorectal adenoma after screening colonoscopy with adenoma polypectomy. J Chin Med Assoc. 2014; 77:508–512.

24. Kim MC, Jung SW, Kim CS, Chung TH, Yoo CI, Park NH. Metabolic syndrome is associated with increased risk of recurrent colorectal adenomas in Korean men. Int J Obes (Lond). 2012; 36:1007–1011.

25. Park HW, Byeon JS, Yang SK, Kim HS, Kim WH, Kim TI, et al. Colorectal neoplasm in asymptomatic average-risk Koreans: the KASID prospective multicenter colonoscopy survey. Gut Liver. 2009; 3:35–40.

26. Kitahara CM, Berndt SI, de González AB, Coleman HG, Schoen RE, Hayes RB, et al. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2013; 31:2450–2459.

27. Ng SC, Wong SH. Colorectal cancer screening in Asia. Br Med Bull. 2013; 105:29–42.

28. Hsu YC, Chiu HM, Liou JM, Chang CC, Lin JT, Liu HH, et al. Glycated hemoglobin A1c is superior to fasting plasma glucose as an independent risk factor for colorectal neoplasia. Cancer Causes Control. 2012; 23:321–328.

29. Kim BJ, Kim YH, Sinn DH, Kang KJ, Kim JY, Chang DK, et al. Clinical usefulness of glycosylated hemoglobin as a predictor of adenomatous polyps in the colorectum of middle-aged males. Cancer Causes Control. 2010; 21:939–944.

30. Sasaki Y, Takeda H, Sato T, Orii T, Nishise S, Nagino K, et al. Serum Interleukin-6, insulin, and HOMA-IR in male individuals with colorectal adenoma. Clin Cancer Res. 2012; 18:392–399.

31. Otani T, Iwasaki M, Ikeda S, Kozu T, Saito H, Mutoh M, et al. Serum triglycerides and colorectal adenoma in a case-control study among cancer screening examinees (Japan). Cancer Causes Control. 2006; 17:1245–1252.

32. Sun ZJ, Huang YH, Wu JS, Yang YC, Chang YF, Lu FH, et al. The association of serum lipids with the histological pattern of rectosigmoid adenoma in Taiwanese adults. BMC Gastroenterol. 2011; 11:54.

33. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013; 104:9–14.

34. Esteve E, Ricart W, Fernández-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005; 24:16–31.

35. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol. 2006; 169:1505–1522.

36. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013; 8:e71583.

37. Liu Y, Tang W, Wang J, Xie L, Li T, He Y, et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control. 2014; 25:237–249.

38. Kim YH, Noh R, Cho SY, Park SJ, Jeon SM, Shin HD, et al. Inhibitory effect of metformin therapy on the incidence of colorectal advanced adenomas in patients with diabetes. Intest Res. 2015; 13:145–152.

39. Cho YH, Ko BM, Kim SH, Myung YS, Choi JH, Han JP, et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest Res. 2014; 12:139–145.

40. Broughton T, Sington J, Beales IL. Statin use is associated with a reduced incidence of colorectal adenomatous polyps. Int J Colorectal Dis. 2013; 28:469–476.

41. Marks AR, Pietrofesa RA, Jensen CD, Zebrowski A, Corley DA, Doubeni CA. Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2015; 24:1692–1698.